Post Date: December 9, 2020
The third patient to participate in a clinical trial of a sickle cell gene therapy showed encouraging response to a treatment produced through an enhanced manufacturing process, according to data presented Dec. 7, 2020, at the 62nd American Society of Hematology (ASH) Annual Meeting.
The treatment, now being developed by Aruvant Sciences, a spin-off company co-launched by Cincinnati Children’s, is being studied in a phase 1/2 clincal trial called MOMENTUM.
“ARU-1801 demonstrated clinically meaningful long-term reductions in sickle cell disease burden,” said Michael Grimley, MD, Medical Director of the Division of Bone Marrow Transplantation and Immune Deficiency at the Cincinnati Children’s. “The potentially curative efficacy seen from the new manufacturing process and three year durability demonstrated by the first treated patient show that ARU-1801, given with only reduced intensity conditioning, can be an important and more tolerable treatment option for patients with severe SCD.”
The company used a new manufacturing process to treat “patient 3” in the study. Outcomes have included:
This Phase 1/2 study is currently enrolling participants, and information may be found at www.momentumtrials.com.
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.